210. 単心室症 Single Ventricle Clinical trials / Disease details


臨床試験数 : 51 薬物数 : 53 - (DrugBank : 22) / 標的遺伝子数 : 32 - 標的パスウェイ数 : 67

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-022389-28-DK
(EUCTR)
12/11/201026/10/2010Treatment with Endothelinantagonist to tcpc patients; a multicenter, randomized, Prospective study measuring maximal O2 uptake in ergometer bicycle test.[TEMPO-study].Treatment with Endothelinantagonist to tcpc patients; a multicenter, randomized, Prospective study measuring maximal O2 uptake in ergometer bicycle test.[TEMPO-study]. Patients with a univentricular heart, who have recieved paliating surgery in the form of TCPC operation
MedDRA version: 14.1;Level: PT;Classification code 10021076;Term: Hypoplastic left heart syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders
Trade Name: TracleerLars SøndergaardNULLNot RecruitingFemale: yes
Male: yes
Denmark
2EUCTR2005-005898-29-GB
(EUCTR)
04/07/200809/05/2008The effect of bosentan, a selective endothelin antagonist, on cardiovascular performance in patients with a Fontan circulation - Bosentan therapy in FontansThe effect of bosentan, a selective endothelin antagonist, on cardiovascular performance in patients with a Fontan circulation - Bosentan therapy in Fontans Patients with a Fontan circulation (that is they have had a Fontan operation for a functionally univentricular heart)
MedDRA version: 9.1;Level: LLT;Classification code 10045545;Term: Univentricular heart
MedDRA version: 9.1;Classification code 10065950;Term: Cavopulmonary anastomosis
MedDRA version: 9.1;Classification code 10037456;Term: Pulmonary vascular resistance abnormality
Trade Name: Tracleer
Product Name: bosentan
INN or Proposed INN: Bosentan
INN or Proposed INN: Bosentan
University Hospital BirminghamNULLNot Recruiting Female: yes
Male: yes
15 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesUnited Kingdom